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DOI 10.1186/s13054-016-1578-9RESEARCH Open AccessThe role of total cell-free DNA in
predicting outcomes among trauma
patients in the intensive care unit: a
systematic review
Mikail Gögenur*, Jakob Burcharth and Ismail GögenurAbstract
Background: Cell-free DNA has been proposed as a means of predicting complications among severely injured
patients. The purpose of this systematic review was to assess whether cell-free DNA was useful as a prognostic
biomarker for outcomes in trauma patients in the intensive care unit.
Methods: We searched Pubmed, Embase, Scopus and the Cochrane Central Register for Controlled Trials and
reference lists of relevant articles for studies that assessed the prognostic value of cell-free DNA detection in trauma
patients in the intensive care unit. Outcomes of interest included survival, posttraumatic complications and severity
of trauma. Due to considerable heterogeneity between the included studies, a checklist was formed to assess
quality of cell-free DNA measurement.
Results: A total of 14 observational studies, including 904 patients, were eligible for analysis. Ten studies were
designed as prospective cohort studies; three studies included selected patients from a cohort while one study was
of a retrospective design. We found a significant correlation between higher values of cell-free DNA and higher
mortality. This significant correlation was evident as early as on intensive care unit admission. Likewise, cell-free
DNA predicted the severity of trauma and posttraumatic complications in a majority of patients.
Conclusion: The amount of cell-free DNA can function as a prognostic tool for mortality and to a lesser extent
severity of trauma and posttraumatic complications. Standardizing cell-free DNA measurement is paramount to
ensure further research in cell-free DNA as a prognostic tool.
Keywords: cfDNA, mtDNA, nDNA, Trauma, Intensive care unitBackground
In recent years cell-free DNA (cfDNA) has become in-
creasingly used as a clinical and noninvasive biomarker in
the fields of cancer [1–3], pre-natal diagnostics [4], organ
transplantation [5], and in several emergency conditions
[6–8]. cfDNA, defined as extracellular DNA circulating
freely in the blood, can be further subcategorized to circu-
lating mitochondrial DNA (mtDNA) and circulating
nuclear DNA (nDNA). Within cancer research, cfDNA
has been proposed to have the ability to act as a nonin-
vasive biopsy of the tumor (i.e., liquid-biopsy) [9] and* Correspondence: mgog@regionsjaelland.dk
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(http://creativecommons.org/publicdomain/zeas a prognostic marker for clinical outcomes such as
disease burden [3], progression-free survival [10], and
overall survival [11].
In patients admitted to an intensive care unit (ICU) as
a result of trauma, cfDNA has received increasing atten-
tion under the hypothesis that cfDNA originates from
cell death [12, 13] and could correlate with the severity
of trauma with prognostic and predictive abilities. Prelim-
inary reports have confirmed that the amount of cfDNA
correlates inversely to mortality [14], trauma severity [15],
and post-traumatic complications [16]. Due to the short
half-life of cfDNA [17], it is suitable as a marker of the pa-
tient’s condition in the immediate emergency phase.
mtDNA has also been increasingly investigated inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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gued that mtDNA could be considered a damage-
associated molecular pattern (DAMP). It is well estab-
lished that circulating DAMPs lead to an increase in
the innate immune response [18], possible leading to
a systematic inflammatory response syndrome (SIRS)
[19].
The use of cfDNA as a predictive marker of clinical
outcome have not been systematically analyzed. The aim
of this study was to review the literature on cfDNA as a
predictive marker of clinical outcomes as measured in
trauma patients in ICUs.Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement [20].Eligibility criteria
The inclusion criteria for studies in this review were co-
hort human studies that investigated levels of cfDNA in
plasma or serum in trauma patients aged ≥18 years in
the ICU. Trauma was defined as all grades of trauma
ranging from minor to severe trauma, including isolated
traumatic brain injury (TBI) that resulted in ICU admis-
sion. Studies exclusively evaluating circulating RNA as
well as studies conducted outside the ICUs were excluded.
A thorough assessment of the quality of DNA sampling
and processing was conducted for all included studies
using previous definitions [21] (see Additional file 1). We
included studies that analyzed DNA by specific sequen-
cing (beta-globin, GAPDH, NADH dehydrogenase) or
fluorescent methods. We only included published studies
and only studies published in the English language.Study search
A computerized comprehensive search strategy was con-
ducted using four databases (PubMed, EMBASE, SCOPUS,
and the Cochrane Central Register for Controlled Trials)
from January 1974 to January 2016. The search was per-
formed on 20 January 2016. The following literature search
was used in PubMed: “(circulating cell free dna) OR cfdna)
OR circulating nucleic acids) OR cell free mitochondrial
DNA) OR nDNA) AND (injury) OR trauma) OR stress)
OR surgery) OR intensive care unit) OR perioperative) OR
postoperative) OR intraoperative) OR preoperative)”.
The literature search was adapted from the PubMed lit-
erature search to EMBASE, SCOPUS, and the Cochrane
Central Register for Controlled Trials. We supplemented
the structured literature search with searching of the refer-
ence lists from the included articles in order to find add-
itional eligible studies.Study selection
The Cochrane systematic review tool Covidence.org was
used in the screening process. Two reviewers (MG and
JB) independently screened titles and abstracts until the
full-text articles were found. Two authors (MG and JB)
independently assessed the full-text articles. Whenever
different opinions emerged a third author (IG) was in-
cluded in the discussion until consensus was reached.Data collection and data items
All included articles were assessed for the following in-
formation: publication details, study method, patient de-
tails, specific time points of cfDNA measurements,
mortality, post-traumatic complications, and trauma se-
verity. This data was collected using a data sheet.Risk of bias of individual studies
Risk of bias assessment was performed by two authors
(MG and JB) using an adapted version of the Scottish
Intercollegiate Guidelines Network (SIGN) (http://www.
sign.ac.uk/methodology/checklists.html) checklist for co-
hort studies [22]. The SIGN checklist evaluates selection
bias, performance bias, attrition bias, detection bias, and
statistical analysis. All studies were assigned up to 8 points
if they met the SIGN checklist criteria. Studies with 8
points were considered to be high quality (HQ) studies
with little or no risk of bias, while studies between 6 and 7
and 0 and 5 were considered acceptable quality (AQ) with
an associated risk of bias and unacceptable quality with a
high risk of bias, respectively.
One point was given for every checkpoint met, while
studies with insufficient information regarding a check-
point were given 0 points. Checkpoints not applicable
for certain studies were given 1 point as it was not con-
sidered a shortcoming of the quality of the study.
Different techniques and methods have been devel-
oped over the past years to process and analyze cfDNA.
This was taken into consideration by a thorough assess-
ment of DNA sampling and processing in all included
studies using previously described methods [21] on
the quality of cfDNA processing and analyses (see
Additional file 1). We adopted these recommendations of
cfDNA processing into a list of checkpoints for each
study. Checkpoints considered the type of medium for
analysis (plasma or serum), the amount and speed of cen-
trifugation, type of sample tube, freezing of samples and
under which conditions (–20 or –80 °C), and finally if
blood had been processed before 4 hours. The results of
these assessments were collected on the same data sheet
as outcomes. Greater than 5 points were deemed as high-
quality circulating DNA processing, 3–4 points were
deemed as acceptable quality, while 0–2 points were con-
sidered unacceptable quality. The quality of the DNA
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bustness of study conclusions.
Results
Study selection
The search identified 2728 potential studies (see Fig. 1),
where 2710 studies by title and abstract screening were
deemed irrelevant. Of the remaining 18 studies, six stud-
ies were excluded for the following reason: four studies
were based on nontrauma patients [23–26] and two
studies included both ICU and nonICU patients [27, 28].
A total of 15 studies from 14 references were included in
this systematic review of which two studies were added
after examining the included studies’ references lists (see
Fig. 1). Ten studies were designed as prospective cohort
studies, three studies included selected patients from a co-
hort, while one study included retrospective patients.
Study characteristics
The main characteristics and cfDNA processing score
(see Additional file 2 for information regarding specific
points) of the included studies are summarized in
Table 1. A total of 904 patients were included in the
period 1996–2013 with a sample size range of 25–188.
One reference presented results from two studies lead-
ing to two separate DNA processing and risk of biasFig. 1 Flow diagram. PRISMA flow diagram of included studies in qualitativassessments [29]. Ten studies included nonspecific
trauma patients while five studies included patients with
TBI with or without extracranial trauma [16, 30–36].
Nine of the nonspecific trauma studies based severity of
trauma on the Injury Severity Score (ISS) [14, 15, 29,
34–38], while one used both the Acute Physiology and
Chronic Health Evaluation (APACHE) II and Sepsis-
related Organ Failure Assessment (SOFA) score [39]. All
TBI studies used the Glasgow Coma Scale (GCS) to clas-
sify the effects of the trauma while using either the ab-
breviated injury scale (AIS), ISS, or APACHE II to
describe the severity of trauma. The DNA processing
score ranged from 2–5 (Table 1). All studies measured
cfDNA on ICU admission, while eight studies also
measured cfDNA at different time points during the
admission period.
The patient population differed to some extent be-
tween the studies. Ten studies included all trauma pa-
tients in the ICU [14, 15, 29, 34–39], while five studies
required patients to be diagnosed with TBI [16, 30–33].
One study only included male patients [32]. Treatment
strategies during ICU admission were not described,
which mean that different treatments might have been
used. There is a risk of bacterial DNA contamination in
DNA assessment methods, but only one study reported
on bacterial DNA analyses [38].e synthesis. ICU intensive care unit
Table 1 Study characteristics
Author Method Patients,
n
Age, years Sex male,
n (%)
Time of
measurement
Severity score (n) [range] DNA
measurement
scorea
Nonspecific trauma
Ren et al.
(2013) [37]
Cohort study 56 38 ± 14 47
(83.9%)
1–6 h, 24–36 h,
60–90 h
ISS, minor: 4.8 ± 1.7 (16)
ISS, moderate: 11.1 ± 1.9 (19)
ISS, severe: 33.7 ± 20.0 (21)
4
Margraf et al.
(2008) [15]
Prospective
cohort
37 45 ± 21.3 24
(64.9%)
ICU admission,
1–10 days
ISS, 31.6 ± 11 [16–50] 5
Lo et al.
(2000) [14]
Retrospective
study
84 ICU admission ISS, minor/moderate:
<16 (47)
ISS, major: ≥16 (37)
3
Wijeratne et al.
(2004) [39]
Cohort study 96 63 (25–85) 69
(73.4%)
ICU admission ? 5
Lam et al.
(2003) [29]
Observational
study
25 38 24
(63.2%)
Study 1: ICU admission,
every 20 min for 180 min
Study 2:
ICU admission every
day for 28 days
ISS, minor: <9 (4)
ISS, moderate: 8–15 (10)
ISS, severe:16–24 (7)
ISS, very severe: >25 (4)
3
McIlroy et al.
(2014) [43]
Prospective
cohort and
healthy controls
35 38 (29–48) 25
(71.4%)
Preoperative, immediately
postoperative,
7 h postoperative,
24 h postoperative,
3 days postoperative,
5 days postoperative
Median ISS: 14 [9-22] 4
Yamanouchi
et al. (2013) [34]
Prospective
study
37 56 (35–70) 26
(70.2%)
ICU admission, days 1–2
and day 4
AIS >3
SOFA score (day 1) 2 [2-4]
APACHE II score (day 1) 11 [6-15]
2
Lam et al.
(2004) [36]
Prospective
cohort and
healthy controls
38 NA NA ICU admission ISS <16 (28)
ISS >16 (10)
4
Gu et al.
(2013) [35]
Prospective
cohort and
healthy controls
86 45.5
(28.75–57.25)
61
(70.1%)
ICU admission SIRS absent ISS 14
[9.75-18.25] (50)
SIRS present ISS 22
[18-29] (36)
SIRS present APACHE II
11.5 [8-16]
SIRS absent APACHE II
9 [6-11]
4
Traumatic brain injury
Macher et al.
(2012) [30]
Prospective
cohort and
healthy controls
65 38.18 ± 2.02 56 (86%) ICU admission, 24 h,
48 h, 72 h and 96 h
postoperative
GCS: 7 [3-9]
ISS: 36 [9-75]
APACHE II: 19 [5-34]
2
Shaked et al.
(2014) [31]
Selected
patients from
a cohort
28 49 (18–91) 23
(82.1%)
ICU admission GCS ≥14 (14)
GCS ≤13 (14)
AIS 0–2 (10)
AIS 3–5 (18)
Yurgel et al.
(2007) [32]
Selected
patients from
a cohort
41 34 (18–64) 41
(100%)
Study entry, 24 h later GCS survivors: 6.5
GCS nonsurvivors: 5
APACHE II survivors:
12.5 APACHE II
nonsurvivors: 18.3
2
Filho et al.
(2014) [33]
Prospective
cohort and
healthy controls
188 34.8 (13.9) 165
(88%)
ICU admission GCS survivors: 6.3
GCS nonsurvivors: 5.2
4
Wang et al.
(2014) [16]
Prospective
cohort
88 36 (20–
53.75)
55
(62.5%)
ICU admission, 4 days,
7 days
GCS: 15 [13-15]
ISS: 16 [11-20]
4
Values are given as mean ± SD or median (interquartile range) unless indicated otherwise
AIS abbreviated injury scale, APACHE Acute Physiology and Chronic Health Evaluation, GCS Glasgow Coma Scale, ICU intensive care unit, ISS Injury Severity Score,
NA not available, SOFA Sepsis-related Organ Failure Assessment, SIRS systemic inflammatory response syndrome
aEvery study was assessed for cfDNA sampling and analysis: 1 point was given if circulating DNA was analyzed in plasma; 1 point was given if blood was collected in
either an EDTA tube or cell-free DNA tube; 1 point was given if blood was processed before 4 h; 1 point was given if blood was centrifuged one or more times; 1 point
was given if blood was frozen at –80 °C or –20 °C depending on whether cfDNA analysis was based on specific sequence or cfDNA quantification, respectively
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Risk of bias assessments are presented in Additional file
3. According to the adapted version of the SIGN check-
list (Additional file 4), one study was rated as a high-
quality study [16] while 13 studies were rated as being of
acceptable quality and one was rated as of unacceptable
quality. Eleven of 15 studies had control groups [14, 16,
30–33, 35–39]; 12 studies failed to deliver adjusted con-
fidence intervals [14, 15, 29–31, 34, 36–39], and a total
of five studies were deemed to have a high risk of selec-
tion bias as a consequence of a retrospective design [14],
failure to provide exclusion criteria [39], and nonconsec-
utive patient inclusion [29, 32]. A possibility of detection
bias was assessed in 11 of 15 groups as a consequence of
these not providing information regarding the blinding
of essential risk factors such as severity of trauma or
clinical outcome [14, 15, 30–32, 34–39].
Two studies were considered as high-quality studies
based on DNA processing [15, 39] while nine were
deemed of acceptable quality [14, 16, 29, 33, 35–38] and
three presented with an unacceptable quality of DNA
processing [30, 32, 34]. One study was not assessed as
no information regarding blood sampling and processing
was available [31]. Twelve of 15 studies used plasma
[14–16, 29, 32–39]. All studies centrifuged blood sam-
ples prior to freezing. None of the TBI studies stored the
samples at –80 °C while 9 of 10 nonspecific trauma
studies did [15, 29, 34–39].
Results of individual studies
Severity of trauma and post-traumatic complications
The main outcomes are presented in Table 2. In a study
of 56 patients, no correlation was found between sever-
ity of trauma scored with ISS and levels of cfDNA [37];
however, four other studies found a significant correl-
ation between cfDNA and ISS score. Patients diagnosed
with acute lung injury (ALI) or acute respiratory distress
syndrome (ARDS) had significantly higher cfDNA com-
pared to patients without these diagnoses [14]. This cor-
responds to a study which proved that repeatedly
measured levels of cfDNA 1 h, 2 h, and 3 h after ICU
admission in 25 patients at all time points were signifi-
cantly correlated with a higher degree of injury [29]. ISS
scores were also correlated to cfDNA in a prospective
study from 2008 on 37 patients [15] which investigated
cfDNA originating from neutrophils using a fluorescent
method, which was able to identify three different types
of cfDNA kinetics. Type 1 kinetics were characterized by
an initial value of cfDNA below 800 ng/mL followed by
a rapid decrease. Type 2 kinetics were characterized by
initial values above 800 ng/mL followed by a rapid de-
crease. Type 3 kinetics of cfDNA was characterized by
high initial values above 800 ng/mL and a rapid decrease
on days 1–5 followed by a significant increase of cfDNAon days 7–10 compared to type 1 and 2 kinetics. Type 3
kinetics were also associated with a higher ISS score, but
not significantly. A significant association between type
3 kinetics and sepsis was found.
SOFA and APACHE II scores were investigated in a
study on 96 patients which found that higher levels of
cfDNA significantly correlated with higher SOFA scores
but not with APACHE II score [39]. A study measuring
mtDNA in trauma patients found a significant correlation
between mtDNA levels in the plasma and APACHE II and
ISS scores [35]. Similar results were found in two other
studies [34, 36], but one study did not find an association
between mtDNA levels and APACHE II score [34].
In a study on patients with severe TBI, high APACHE
II and ISS scores were significantly correlated with
higher levels of cfDNA 24 h after ICU admission. This
study also showed that patients with high GCS score
(11–15) had significantly lower cfDNA at both ICU ad-
mission and after 24 h [30], which was confirmed in a
similar study [33]. However, a significant correlation be-
tween patients with isolated TBI and patients with extra-
cranial injuries was not found for cfDNA levels in 41
male patients with TBI [32].
Regarding nDNA, similar results have been presented
where patients with high nDNA had lower GCS scores
and significantly higher ISS scores [16]. However, one
study, reporting on both nDNA and mtDNA, found no
correlation between levels of nDNA and mtDNA in rela-
tion to SIRS or multi-organ failure (MOF) [38].
Survival
Survival data in relation to cfDNA was presented in ten
studies. One study reported not being powered to present
survival data [38], while three references did not present
survival data analyzed in relation to cfDNA levels [29, 35,
37]. In the earliest study measuring cfDNA in a retro-
spective population of trauma patients, it was found that
all patients who died in the ICU had significantly higher
cfDNA than survivors [14]. Likewise, it has been reported
that nonsurvivors had a 2.3-fold higher cfDNA level than
survivors [39]. In a prospective cohort of 37 patients,
lower cfDNA levels at ICU admission had a negative pre-
dictive value (NPV) of 100% in relation to death [15]. In
another study, survivors presented significantly lower
cfDNA levels on ICU admission and 24 h after, but not
48 h after, ICU admission [30]. Other authors only found
this significant correlation at 24 h after ICU admission
[31–33]. Two of the studies measuring mtDNA presented
survival data, both showing nonsurviving patients with
significantly higher mtDNA than survivors [34, 36]. Fi-
nally, in a prospective study of 88 patients where nDNA
was measured at ICU admission and on days 4 and 7, pa-
tients with a fatal outcome had significantly higher nDNA
at all time points [16].
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This systematic review found strong evidence in favor of
using cfDNA as a prognostic tool in relation to mortality
in trauma patients admitted to the ICU. We found that
cfDNA can be used as a prognostic tool for the outcome
of post-traumatic complications and the severity of
trauma to a moderate extent.
With regard to linking cfDNA levels to clinical out-
comes such as mortality and complications, we found
that all of the included studies that presented survival
data concluded that higher levels of cfDNA were signifi-
cantly correlated to a higher mortality rate. It seems that
cfDNA levels measured even at the earliest stages of
ICU admission were able to predict a higher mortality
rate [14, 31, 36, 39]. This finding was confirmed in 108
patients with sepsis [7]. Likewise, increasing levels of
nDNA and mtDNA were significantly associated with in-
creasing mortality [30, 31]. With regard to associating
cfDNA levels with development of complications, the re-
sults were not conclusive. One study found that patients
with high initial cfDNA and elevated levels of cfDNA on
days 7 to 10 after ICU admission were significantly asso-
ciated with sepsis [15]. Similar results were found in a
study on a mixed population of ICU patients where
cfDNA was measured on ICU admission, which found
that cfDNA was higher in patients developing sepsis
(p = 0.03) and in nonsurviving patients (p > 0.001)
[40]. However, another prospective study on 160 con-
secutive ICU patients could not confirm these results
[8], which may be due to the cfDNA processing.
Interestingly, regarding the prognostic capabilities of
cfDNA, it was found that cfDNA levels were superior
to classification systems such as multiple organ dys-
function syndrome (MODS) regarding complications
or APACHE II scores regarding mortality [41].
This systematic review has limitations as well as
strengths. A strength of this review is that all of the in-
cluded studies calculated severity score analysis of the
trauma patients, and that the cfDNA levels were corre-
lated to these scores. In general, high severity scores cor-
related to higher levels of cfDNA. A limitation is that
even though we searched widely in four databases, the
result of our search strategy may have been subject to
publications bias, which we were not able to adjust for.
Another limitation was that the patient populations dif-
fered to some extent between the included studies,
which rendered it impossible to perform meta-analysis
on the outcomes. No information regarding treatment
strategies or regimes in the respective hospitals were
available, which could lead to differences in outcome
based on different treatments. Heterogeneity in cfDNA
sampling and processing were found, which made direct
comparison of the results difficult. Only one study re-
ported on bacterial DNA analysis.An interesting aspect of mtDNA is the hypothesis of
mtDNA acting as a DAMP. In the light of the study by
Xiao and collegues [42], where circulating leukocyte
transcriptome after severe trauma and burn injury was
measured, it could be argued that mtDNA is a corner-
stone of the immune reaction. They found that following
severe trauma and burn injury a global reprioritization
occurs in >80% of the cellular functions and pathways, a
phenomenon they call a “genomic storm”. The forma-
tion of neutrophil extracellular traps by mtDNA has also
been proposed as another factor in immune reaction fol-
lowing trauma [43]. Another study where nDNA and
mtDNA was associated with immune function was the
study by Timmermanns et al. [44], who found that
nDNA but not mtDNA correlated negatively with hu-
man leukocyte antigen (HLA-DR) expression, suggesting
that nDNA could possibly function as a DAMP.
With regard to the future of cfDNA research in the
trauma field it is of utmost importance that the correct
methods of cfDNA sampling and processing are used so
that cfDNA is correctly analyzed. It could be argued that
cfDNA should be measured pre- and postsurgery as some
of the same mechanics comes into action during surgery
as in trauma. Ren et al. found that two patients who re-
peatedly underwent surgery had increased cfDNA levels
after each surgery [37]. This aspect of cfDNA could be
very interesting if the same prediction and prognostic pat-
tern could be observed in patients undergoing surgery.
cfDNA could also be viewed as a tool in identifying
trauma patients who need immediate treatment.
Conclusion
This systematic review provides an overview of the possible
benefits of measuring cfDNA in relation to mortality, sever-
ity of trauma, and post-traumatic complications in trauma
patients in the ICU. Moreover, it illustrates important as-
pects of DNA sampling and processing that should be con-
sidered when implementing cfDNA as measurement of
injury severity. Finally, it encourages further research in this
area with the aforementioned guidelines for DNA process-
ing. The value of cfDNA, nDNA, and mtDNA should be
investigated in patients undergoing major elective surgery.
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